The Asia Pacific Vulvovaginal Candidiasis Treatment Market should witness market growth of 5.3% CAGR during the forecast period (2022-2028).
The rising awareness regarding VVC in developing nations, as well as the rise in patient inclination towards maintaining genital health, is further raising the demand for vulvovaginal candidiasis treatment. A large proportion of women across the globe have a weak immune system which raises the risk of vulvovaginal candidiasis. Therefore, various market players are increasing investment in research & development activities and clinical trials of drugs.
Getting yeast infections is very common among pregnant women. This happens due to increased estrogen in the body of pregnant women, which may lead to throwing off the normal balance of bacteria and yeast in the vagina, thereby resulting in yeast overgrowth. Most yeast infections during pregnancy often result from the fungus candida Albicans.
The treatment of vulvovaginal candidiasis majorly focuses on suppositories and intravaginal cream. Nowadays, oral fluconazole is majorly used for the treatment of acute vulvovaginal candidiasis. Also, gynecologists prefer pre-intravaginal preparations due to their limited systematic absorption and possible minimal side effects.
Regional nations such as India are among the largest providers of generic drugs. India is a major producer as well as consumer in the pharmaceutical sector. India is among the major exporters of pharmaceutics across more than 200 nations. The rising focus of the government of several regional nations on menstrual hygiene, as well as awareness regarding women's health, is further supporting the expansion of the femtech industry in the Asia region. Considering all these elements, the market for vulvovaginal candidiasis treatment would expand in the region during the projection period.
The China market dominated the Asia Pacific Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $101.5 million by 2028. The Japan market is registering a CAGR of 4.7% during (2022-2028). Additionally, The India market would showcase a CAGR of 5.9% during (2022-2028).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
The rising awareness regarding VVC in developing nations, as well as the rise in patient inclination towards maintaining genital health, is further raising the demand for vulvovaginal candidiasis treatment. A large proportion of women across the globe have a weak immune system which raises the risk of vulvovaginal candidiasis. Therefore, various market players are increasing investment in research & development activities and clinical trials of drugs.
Getting yeast infections is very common among pregnant women. This happens due to increased estrogen in the body of pregnant women, which may lead to throwing off the normal balance of bacteria and yeast in the vagina, thereby resulting in yeast overgrowth. Most yeast infections during pregnancy often result from the fungus candida Albicans.
The treatment of vulvovaginal candidiasis majorly focuses on suppositories and intravaginal cream. Nowadays, oral fluconazole is majorly used for the treatment of acute vulvovaginal candidiasis. Also, gynecologists prefer pre-intravaginal preparations due to their limited systematic absorption and possible minimal side effects.
Regional nations such as India are among the largest providers of generic drugs. India is a major producer as well as consumer in the pharmaceutical sector. India is among the major exporters of pharmaceutics across more than 200 nations. The rising focus of the government of several regional nations on menstrual hygiene, as well as awareness regarding women's health, is further supporting the expansion of the femtech industry in the Asia region. Considering all these elements, the market for vulvovaginal candidiasis treatment would expand in the region during the projection period.
The China market dominated the Asia Pacific Vulvovaginal Candidiasis Treatment Market by Country in 2021; thereby, achieving a market value of $101.5 million by 2028. The Japan market is registering a CAGR of 4.7% during (2022-2028). Additionally, The India market would showcase a CAGR of 5.9% during (2022-2028).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Oral, Intravenous and Topical. Based on Drug Class, the market is segmented into Fluconazole, Clotrimazole, Terconazole, Terbinafine, Nystatin, Ketoconazole and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
Scope of the Study
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Route of Administration
- Oral
- Intravenous
- Topical
By Drug Class
- Fluconazole
- Clotrimazole
- Terconazole
- Terbinafine
- Nystatin
- Ketoconazole
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG
- Bristol Myers Squibb Company
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional S.A.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Vulvovaginal Candidiasis Treatment Market by Distribution Channel
Chapter 4. Asia Pacific Vulvovaginal Candidiasis Treatment Market by Route of Administration
Chapter 5. Asia Pacific Vulvovaginal Candidiasis Treatment Market by Drug Class
Chapter 6. Asia Pacific Vulvovaginal Candidiasis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Bayer AG
- Bristol Myers Squibb Company
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC)
- Basilea Pharmaceutica Ltd.
- Scynexis, Inc.
- Grupo Ferrer Internacional S.A.
Methodology
LOADING...
